Castle Biosciences (NASDAQ: CSTL) CCO lines up sale of 22,500 shares
Rhea-AI Filing Summary
CASTLE BIOSCIENCES INC (CSTL) received a Rule 144 notice covering potential sales of its common stock by Chief Commercial Officer Tobin Juvenal. The notice lists 22,500 shares of common stock to be sold through Goldman Sachs & Co. LLC, with an indicated aggregate market value of $787,500, and notes that there were 30,549,507 shares outstanding as of the relevant date.
The shares relate to equity compensation awards, including restricted stock units and restricted stock awards granted between 2022 and 2025. The filing discloses that sales are being made under a selling plan dated December 10, 2025 that is intended to comply with Rule 10b5-1(c), with recent sales reported over the past three months.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
Rule 144 regulatory
Rule 10b5-1(c) regulatory
Restricted Stock Units financial
Restricted Stock Awards financial
Form 144 regulatory
FAQ
What does the Form 144 filing disclose for CASTLE BIOSCIENCES INC (CSTL)?
Is there a trading plan associated with the CSTL Form 144 sales?
AI-generated analysis. How Rhea-AI works. Not financial advice.